97 related articles for article (PubMed ID: 23074283)
1. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.
Eke I; Schneider L; Förster C; Zips D; Kunz-Schughart LA; Cordes N
Cancer Res; 2013 Jan; 73(1):297-306. PubMed ID: 23074283
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis.
Eke I; Storch K; Krause M; Cordes N
Cancer Res; 2013 Oct; 73(19):5869-79. PubMed ID: 23950208
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Eke I; Cordes N
Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the EGFR/β1 integrin connecting proteins PINCH1 and Nck2 radiosensitizes three-dimensional SCC cell cultures.
Rossow L; Eke I; Dickreuter E; Cordes N
Oncol Rep; 2015 Jul; 34(1):469-76. PubMed ID: 26004008
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
7. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
Bonner JA; Yang ES; Trummell HQ; Nowsheen S; Willey CD; Raisch KP
Radiother Oncol; 2011 Jun; 99(3):339-43. PubMed ID: 21704410
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
[TBL] [Abstract][Full Text] [Related]
10. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
11. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.
Skvortsova I; Skvortsov S; Raju U; Stasyk T; Riesterer O; Schottdorf EM; Popper BA; Schiestl B; Eichberger P; Debbage P; Neher A; Bonn GK; Huber LA; Milas L; Lukas P
Radiother Oncol; 2010 Jul; 96(1):108-15. PubMed ID: 20451273
[TBL] [Abstract][Full Text] [Related]
13. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
Lu Y; Li X; Liang K; Luwor R; Siddik ZH; Mills GB; Mendelsohn J; Fan Z
Cancer Res; 2007 Sep; 67(17):8240-7. PubMed ID: 17804738
[TBL] [Abstract][Full Text] [Related]
15. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
16. Effect of EGFR antagonists gefitinib (Iressa) and C225 (Cetuximab) on MnSOD-plasmid liposome transgene radiosensitization of a murine squamous cell carcinoma cell line.
Epperly MW; Franicola D; Zhang X; Nie S; Greenberger JS
In Vivo; 2006; 20(6B):791-6. PubMed ID: 17203769
[TBL] [Abstract][Full Text] [Related]
17. Radiation-induced dimer formation of EGFR: implications for the radiosensitizing effect of cetuximab.
Kiyozuka M; Akimoto T; Fukutome M; Motegi A; Mitsuhashi N
Anticancer Res; 2013 Oct; 33(10):4337-46. PubMed ID: 24123001
[TBL] [Abstract][Full Text] [Related]
18. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.
Jouan-Hureaux V; Boura C; Merlin JL; Faivre B
Microvasc Res; 2012 Mar; 83(2):131-7. PubMed ID: 21820450
[TBL] [Abstract][Full Text] [Related]
19. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
20. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Wong TW; Kramer RA; Wild R; Lee FY
Clin Cancer Res; 2005 Aug; 11(15):5558-65. PubMed ID: 16061873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]